Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2023: USD 50.74 M

Shanghai Yizhong Pharmaceutical Co., Ltd. Revenue is USD 50.74 M for the year ending December 31, 2023, a 48.40% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Shanghai Yizhong Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2022 was USD 34.19 M, a 5,228.24% change year over year.
Shanghai Yizhong Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2021 was USD 641.72 K, a 0.00% change year over year.
Shanghai Yizhong Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Shanghai Yizhong Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd.

CEO	Mr. Jingsong Zhou
IPO Date	Sept. 9, 2021
Location	China
Headquarters	No.79 Renqi Road
Employees	304
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. The company was founded in 2009 and is based in Shanghai, China.

Key trends

Past 5 years